TQB2618 injection
Sponsors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions
Advanced Hepatocellular CarcinomaAdvanced Solid TumorsColorectal CancerMelanomaRelapsed/Refractory Lymphoma
Phase 1
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB2618 Injection in Subjects With Advanced Solid Tumors
NCT04623892
Start: 2020-12-01End: 2021-07-31Target: 50Updated: 2020-11-10
To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients With Relapsed and Refractory Lymphoma
NCT05400876
Start: 2022-06-09End: 2023-10-31Target: 92Updated: 2023-02-14
Efficacy and Safety of TQB2618 Injection Combined With Toripalimab Injection in Patients With Advanced Melanoma
NCT05451407
Start: 2022-08-09End: 2023-12-31Target: 50Updated: 2023-07-07
A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC).
TerminatedNCT05975645
Start: 2023-08-15End: 2025-06-04Updated: 2025-08-12
A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.
NCT06010901
Start: 2024-01-13End: 2025-07-31Target: 75Updated: 2024-01-23